Venetoclax-based low-intensity therapy in pediatric AML: A viable option for chemotherapy-intolerant patients.
1/5 보강
Childhood acute myeloid leukemia (AML) comprises 15-20% of pediatric leukemias and carries promising survival rates (60-70%) in high-income countries with use of intensive chemotherapy.
APA
Dhariwal N, Srinivasan S (2026). Venetoclax-based low-intensity therapy in pediatric AML: A viable option for chemotherapy-intolerant patients.. American journal of blood research, 16(1), 23-27. https://doi.org/10.62347/VCKT6128
MLA
Dhariwal N, et al.. "Venetoclax-based low-intensity therapy in pediatric AML: A viable option for chemotherapy-intolerant patients.." American journal of blood research, vol. 16, no. 1, 2026, pp. 23-27.
PMID
41877936 ↗
Abstract 한글 요약
Childhood acute myeloid leukemia (AML) comprises 15-20% of pediatric leukemias and carries promising survival rates (60-70%) in high-income countries with use of intensive chemotherapy. This is associated with high treatment-related mortality in low- and middle-income countries, especially during induction, due to malnutrition, infections, and insufficient resources. Venetoclax, a BCL-2 inhibitor effective in older adults unfit for standard therapy, has shown potential in pediatric relapse AML. Here, we describe two children with newly diagnosed AML who developed life-threatening toxicities with intensive chemotherapy and were subsequently treated with venetoclax-based low-intensity regimens. Both patients achieved complete remission, attained measurable residual disease negativity, and maintained durable responses with minimal toxicity, allowing largely outpatient management. These cases suggest a promising, feasible alternative for chemotherapy-intolerant patients.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study.
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.
- Current Systemic Treatment Options for Advanced Pancreatic Cancer-An Overview Article.
- A Phase II Study of Durvalumab, Doxorubicin, and Ifosfamide in Recurrent and/or Metastatic Pulmonary Sarcomatoid Carcinoma (KCSG LU-19-24).